The Federal Reserve's final policy meeting of the year arrives at a moment when the stock market is once again within striking distance of record highs. ...

Oracle Corp. heads into its fiscal second-quarter earnings report facing mounting scrutiny from investors, who have grown increasingly uneasy about the software giant's rising leverage, heavy capital ... ...

Rolls-Royce share price has held steady in the past few days, moving from a low of 1,020p on November 24 to the current 1,110p. It has jumped by over 100% from its lowest level in January and is a few points below the year-to-date high of 1,195p. So, is it still safe to buy the RR stock? Copy link to section Rolls-Royce, the giant British engine manufacturer, has been one of the best-performing companies in the FTSE 100 Index this year, helped by the robust demand of its products across its verticals like c ...

Core Insights - Nintendo's shares have experienced a decline of up to 2.6%, highlighting a broader trend in the tech supply chain related to increasing memory costs affecting gaming hardware [1] Industry Impact - The rising memory costs are causing significant ripples throughout the gaming hardware sector, indicating potential challenges for companies reliant on these components [1]

JPMorgan stock (NYSE: JPM) tanked nearly 5% on Tuesday after the bank's consumer banking chief warned that 2026 expenses will reach $105 billion. Wall Street wasn't pricing in this magnitude of expens... ...

Core Insights - Pfizer is pursuing a new opportunity in the obesity treatment market by signing an exclusive global license agreement with YaoPharma, a subsidiary of China's Fosun Pharma [1] Company Summary - Pfizer is focusing on developing an oral obesity pill, indicating a strategic move to expand its product portfolio in the obesity treatment sector [1] - The collaboration with YaoPharma suggests Pfizer's intent to leverage partnerships to enhance its market presence in China and potentially other regions [1] Industry Summary - The obesity treatment market is gaining attention, with pharmaceutical companies exploring innovative solutions to address the growing prevalence of obesity globally [1] - The partnership between Pfizer and YaoPharma reflects a trend of international collaboration in the pharmaceutical industry, particularly in the development of specialized treatments [1]

Famed investor Jim Cramer says he "salutes†DaviCVSd Joyner after CVS Health (NYSE: CVS) raised its profit guidance for 2026 – reinforcing the new management's turnaround plan is starting to bear frui... ...

Twenty One Capital began trading on the New York Stock Exchange under the ticker XXI and fell 25% early in its first day, trading at about $10.50. The New York listing follows the completion of the co... ...

Gold will remain favourable in the short term due to the uncertainties in the geopolitical environment around the world. The ongoing EU plans regarding frozen Russian reserves serve as a further comp... ...

With the Federal Reserve set to announce its final policy decision of 2025 on Wednesday, investors are rotating into defensive positions. More than the rate-cut possibility (which is around 90% as per... ...